Use of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing coronary revascularization.
This paper briefly reviews the results from three recent large-scale clinical trials evaluating the benefit of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes (ACS). The available data suggest that these are promising agents for the management of ACS, particularly in improving the immediate outcome in the acute setting.
Popma
J J
JJ
Departments of Internal Medicine (Cardiology Division), Brigham and Women's Hospital, Boston, Mass., USA.
D000789:Angina, Unstable / Q000188:drug therapy*; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
D000925:Anticoagulants; D019039:Platelet Glycoprotein GPIIb-IIIa Complex